In this study, we selected ROR1 as the target antigen primarily due to its established expression in colorectal adenocarcinomas and its emerging relevance in solid‐tumor‐targeted CAR T‐cell therapies.[35] We acknowledge, however, that ROR1 expression is not entirely restricted to tumor cells in our model, as evidenced by our observation of comparable ROR1 expression levels in HUVECs used within the IAC model. This evidence concerns the gene ROR1 and neoplasm.